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ABSTRACT: Side chain-to-side chain cyclizations represent a
strategy to select a family of bioactive conformations by
reducing the entropy and enhancing the stabilization of
functional ligand-induced receptor conformations. This
structural manipulation contributes to increased target
speciﬁcity, enhanced biological potency, improved pharmaco-
kinetic properties, increased functional potency, and lowered
metabolic susceptibility. The CuI-catalyzed azide−alkyne 1,3-
dipolar Huisgen’s cycloaddition, the prototypic click reaction,
presents a promising opportunity to develop a new paradigm
for an orthogonal bioorganic and intramolecular side chain-to-
side chain cyclization. In fact, the proteolytic stable 1,4- or 4,1-
disubstituted [1,2,3]triazolyl moiety is isosteric with the
peptide bond and can function as a surrogate of the classical side chain-to-side chain lactam forming bridge. Herein we
report the design, synthesis, conformational analysis, and functional biological activity of a series of i-to-i+5 1,4- and 4,1-
disubstituted [1,2,3]triazole-bridged cyclopeptides derived from MT-II, the homodetic Asp5 to Lys10 side chain-to-side chain
bridged heptapeptide, an extensively studied agonist of melanocortin receptors.
■ INTRODUCTION
Melanocortins are a group of peptide hormones including
adrenocorticotropin (ACTH) and α-, β-, and γ-melanocyte
stimulating hormones (MSHs). To date, ﬁve human
melanocortin receptors (MC1R-MC5R) have been character-
ized as belonging to group α of the rhodopsin family of G-
protein coupled receptors (GPCR).1,2 The MCRs mediate a
plethora of biological functions that include sexual function,3
feeding behavior,4,5 pain modulation,6 thermoregulation, energy
homeostasis,7,8 cardiovascular eﬀects, and skin pigmentation,9,10
making them potential drug targets for treating pain, food
intake, and body weight as well as erectile dysfunction.
Therefore, development of an expansive toolbox of structural
modiﬁcations that can be used to ﬁne-tune the predominant
conformations to achieve modulation of speciﬁcity toward
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receptor subtypes, physicochemical and pharmacological
properties continues to be of great interest in the development
of peptide-based drugs in general and melanocortinergic drugs
in particular. Recently, the growing interest in designing highly
selective and potent superagonist of the human melanocortin
receptors hMC3R and hMC4R has been driven by their
prospects of becoming eﬀective drugs for treating feeding
disorders such as the respective obesity and energy homeo-
stasis. Structure−activity relationship studies (SAR) of α-
MSH,11 a post-translationally generated tridecapeptide frag-
ment originating from proopiomelanocortin (POMC),12 led to
the development of MT-II, Nα-Ac[Nle4,c(Asp5,D-Phe7,Lys10)]-
αMSH(4−10)NH2.13−15 This homodetic Asp5 to Lys10 side
chain-to-side chain bridged lactam stabilizes the pharmaco-
phore containing sequence His6-D-Phe7-Arg8-Trp9 in a type-II
β-turn, resulting in a potent long acting nonselective super-
agonist of MCRs.16 Evidently, the plethora of melanocortin-
mediated activities, the ﬁve melanocortin receptor subtypes,
and the high proﬁle of potential therapeutic targets associated
with the melanocortin system underscores the unmet need for
highly selective, pharmacokinetically diverse, and bioavailable
agonists and antagonists. Intramolecular side chain-to-side
chain cyclization of linear peptides is an established approach to
achieve stabilization of speciﬁc conformations and a recognized
strategy to improve resistance toward proteolytic degradation,
increasing the metabolic stability in vitro and in vivo.17,18 We
have previously reported a novel intramolecular i-to-i+4 side
chain-to-side chain [1,2,3]triazolyl-bridged modiﬁcation that is
bioisosteric to the peptide bond and employs the prototypical
click reaction, CuI-catalyzed azido-to-alkyne 1,3-dipolar cyclo-
addition (CuAAC).19 Importantly, the CuAAC does not
require synthetic schemes with elaborate orthogonal protection
strategies. Our studies explored the relationship between the
size of the bridge containing the [1,2,3]triazolyl moiety, the
location of this moiety within the bridge, its orientation relative
Scheme 1. Sequences of the Linear Precursors Nα-Ac[Nle4,Yaa5,D-Phe7,Xaa10]αMSH(4-10)NH2 and of the [1,2,3]Triazolyl-




aAll amino acids except when mentioned otherwise are of the L conﬁguration.
Scheme 2. Sequences of the Linear Precursors Nα-Ac[Nle4,Xaa5,D-Phe7,Yaa10]αMSH(4-10)NH2 and of the [1,2,3]Triazolyl-
Containing Cyclopeptides, Nα-Ac[Nle4,Xaa5(&1),D-Phe7,Yaa10(&2)]αMSH(4−10)NH2 [{&1(CH2)m-1,4-[1,2,3]triazolyl-
(CH2)n&
2}]a
aAll amino acids except when mentioned otherwise are of the L conﬁguration.
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to the peptide backbone, and the predominant conformations
displayed by these heterodetic cyclic peptides.
In the current study, we explored the potential of the i-to-i+5
side chain-to-side chain 1,4- and 4,1-disubstituted [1,2,3]-
triazolyl-containing bridges to stabilize β-turn conformations in
the context of the MT-II scaﬀold and evaluate its potential as a
modulator of receptor subtype selectivity. We synthesized a
series of heterodetic MT-II related cyclo-heptapeptides that
varied in the size of the disubstituted [1,2,3]triazolyl-containing
bridge connecting Cαs of residues 4 and 10 and in the location
and orientation of the [1,2,3]triazolyl moiety within the bridge
(I−X, Schemes 1 and 2). The [1,2,3]triazolyl moiety was
ﬂanked on each side by 1 to 4 methylenes totaling in 4 or 5
methylenes. The biological activity of all the 1,4- and 4,1-
disubstituted-[1,2,3]triazolyl-containing cyclopeptides (I−X,
Table 3) is compared to the prototypic lactam-containing
peptide MT-II, as well as to the linear control precursors (I′−
X′, Tables 2 and 3).
■ SYNTHETIC STRATEGY
In the current study, we explored the potential of the i-to-i+5
side chain-to-side chain 1,4- and 4,1-disubstituted [1,2,3]-
triazolyl-containing bridges to stabilize β-turn structure, which
has been identiﬁed as the MT-II bioactive conformation,
responsible for its protracted, nonselective, and superagonist
activity. To this end, we designed a series of [1,2,3]triazolyl-
containing cyclo-heptapeptides, derived from the model lactam
peptide, MT-II Nα-Ac[Nle4,c(Asp5,D-Phe7,Lys10)]αMSH(4−
10)NH2, that vary in the size of the bridge and the location
and orientation of the [1,2,3]triazolyl moiety within this bridge
(Schemes 1 and 2).
In this context, Nα-Fmoc-ω-azido-α-amino acids (1−4) and
Nα-Fmoc-ω-ynoic-α-amino acids (5−8) with diﬀerent length of
the side chain were introduced in positions i and i+5 to replace
Asp5 and Lys10 residues in the sequence of MT-II (see I′−X′,
Schemes 1 and 2).21,22 The Nα-Fmoc-ω-azido-α-amino acids
(1−4) were synthesized by diazo-transfer reaction starting from
the corresponding Nα-protected α,ω-diamino acids (see
Supporting Information).22 Except for the commercially
available Nα-Fmoc-S-Pra-OH (8), the Nα-Fmoc-ω-alkynyl-α-
amino acids (5−7) were synthesized by alkylation of a Ni(II)
complex of the Schiﬀ base formed between glycine and (S)-2-
(N-benzylprolyl)aminobenzophenone, as a chiral inducer, with
alk-ω-ynyl bromides (see Supporting Information).22 Solid-
phase peptide synthesis (SPPS) generated a series of linear
peptide precursors (I′−X′) in which Lys10 and Asp5 were
replaced with ω-azido- and ω-yl-α-amino acid residues with
side chains containing 1−4 methylenes. The stepwise solid-
phase assembly of the linear precursors I′−X′ was performed
following Fmoc/tBu strategy on Rink-amide type resin.23 The
chemical inertness of the ω-azido and ω-alkynyl functions
toward the entire range of coupling and deprotection reactions
and the various nucleophiles and electrophiles present during
the multistep synthesis24−26 saves the need for elaborate
orthogonal protection schemes. The incorporation of the
building blocks Nα-Fmoc-Xaa(ω-N3)-OH and N
α-Fmoc-Yaa-
(ω-yl)-OH during the SPPS was found to be markedly
advantageous to the postpeptide assembly side chain
modiﬁcation that introduces the ω-azido and ω-ynoic functions
needed for the CuI-catalyzed intramolecular azide−alkyne
cycloaddition.21,22 Solution-phase intramolecular CuAAC con-
verted the linear precursors I′−X′ into the 1,4- and 4,1-
disubstituted-[1,2,3]triazolyl-containing cyclopeptides (I−X),
presenting diﬀerent permutation in terms of the size of the
[1,2,3]triazolyl-containing bridges and the orientation and
position of the [1,2,3]triazolyl moiety within the bridge.
Depending on the positions i or i+5 of the azido and alkynyl
amino acids in the peptide sequences, we generated two classes
of cyclopeptides (Schemes 1 and 2). The intramolecular
CuAAC of the linear precursors (I′−X′) was carried out as
outlined in Scheme 3.
The ﬁrst class employed linear precursors that had ω-yl- and
ω-azido-α-amino acid residues in the respective positions i and i
+5 (I′−IV′ and IX′) and yielded upon CuAAC the cyclo-
peptides presenting the [1,2,3]triazolyl moiety in the 4,1-
orientation (I−IV and IX). The second class employed linear
precursors that had ω-azido- and ω-yl-α-amino acid residues in
the respective positions i and i+5 (V′−VIII′ and X′) and
yielded upon CuAAC the cyclopeptides presenting the
[1,2,3]triazolyl moiety in the 1,4-orientation (V−VIII and X).
The click reaction conditions were identical to those reported
by us previously and used a 10-fold molar excess of CuSO4·
5H2O and ascorbic acid in tBuOH/H2O (1:2, v/v).
21 Under
these conditions, there was no formation of oligomeric
products resulting from intermolecular click reactions, thus
suggesting formation of a CuI/acetylide/azide complex that has
high preference for intramolecular cyclizations. Moreover,
solution-phase CuAAC avoids dimerizations and macrocycliza-
tions, which are often observed in on-resin CuAAC, resulting in
crude products that are easy to purify. All copper salts were
eliminated by solid-phase extraction of the crude material with
water and elution of the cyclopeptides with 10−30% of ACN in
water. The clicked cyclopeptides were further puriﬁed by RP-
HPLC. The linear analogue of MT-II, BE124 (Ac-Nle-Asp-His-
Scheme 3. General Procedure of CuAAC of the Linear Precursors (I′−X′)
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D-Phe-Arg-Trp-Lys-NH2) and the its uncharged variant BE123,
Ac-[Asn5,Lys10(Nε-Ac)]BE124, were synthesized by Fmoc/tBu
SPPS strategy and used as reference compounds in the
biological assays (Table 1 and Table 2).
■ RESULTS AND DISCUSSION
Biological Activity. The potency of MT-II and of the linear
peptide NDP-MSH (Table 1), the superpotent and long acting
agonist,27 the reference peptides BE124 and BE123 (Table 1),
and the precursors (I′−X′), as well as the [1,2,3]triazolyl-
containing cyclopeptides (I−X) (Schemes 1 and 2), was
pharmacologically evaluated for functional potency (EC50) and
eﬃcacy using a reporter gene based bioassay for cAMP in HEK-
293 cells stably expressing the murine (mouse) melanocortin
receptor subtypes mMC1R, mMC3R, mMC4R, and mMC5R
(Tables 2−3).
Table 2 reports the EC50 values in the adenylyl cyclase based
bioassays of the linear peptides: the linear peptide precursors
I′−X′, the classical NDP-MSH, and the MT-II analogues,
BE123 and BE124. Peptide BE123, in which the charges on Asp
and Lys present in BE124 are eliminated, reproduces closely
the eﬀect of side chain-to-side chain cyclization present in MT-
II. As such, short of the conformational rigidiﬁcation, BE123 is
a linear version of MT-II. Table 3 summarizes the functional
agonist potencies of the 1,4- and 4,1-disubstituted-[1,2,3]-
triazolyl-containing cyclopeptides I−X compared to MT-II. In
this study, we used HEK-293 cells stably expressing the murine
melanocortin receptors subtypes mMC1R, mMC3R, mMC4R,
and mMC5R to assess the agonist potency and subtype
selectivity proﬁles of these MT-II mimetic peptides.28,29
Among the linear peptides, NDP-MSH is the most potent
mMC1R agonist, showing an EC50 value that is 5- and 9-fold
lower than the respective values for BE124 and BE123 (Table
2). All three linear peptides are good agonists toward the
mMCR4R, with very similar subnanomolar EC50s (0.20−0.31
nM), and are 4−9-fold lower than their EC50s toward mMC3R
and mMC5R. Relative to the linear peptides, the cyclic MT-II is
the most potent agonist toward all four receptor subtypes. It is
about 2- and 4-fold more potent than NDP-MSH on the
mMC1R and mMC4R, respectively. Moreover, MT-II discrim-
inates nicely between mMC1R or mMC4R and mMC3R or
mMC5R. Interestingly, both BE124 and its potential charge-
bearing side chains blocked variant BE123 are almost
equipotent in all four receptor subtypes. Apparently, the
application of the conformational constraint in the form of i-to-i
+5 side chain-to-side chain lactam bridge formation as in MT-II
and not the neutralization of potential charge-bearing groups as
in BE123 play a critical role in potentiation and enhancement
of functional selectivity toward certain receptor subtypes.
The potencies of the linear peptide precursors I′−X′ (Table
2, Figure 1) span a range of 2 orders of magnitude between the
most potent one X′ (EC50 ≈ 0.050 nM in mMC4R and
mMC5R) and the least potent one II′ (EC50 = 5.33 nM in
mMC5R). Analogue X′ is the most potent of all four receptor
subtypes, with 5−8-fold higher potency on mMC4R and
mMC5R than on mMC1R and mMC3R. The selectivity for
receptor subtype of a single analogue is in the range of 5−10-
fold. For example, IX′ is 10-fold more potent in mMC5R than
in mMC3R (EC50s 0.23 and 2.33 nM, respectively).
The melanocortin receptor subtype related potencies of the
two short linear MT-II-related peptides BE123 and BE124 is
very similar to that of the linear precursors I′−X′ regardless of
the nature of side-chain modiﬁcations in positions 5 and 10 (α-
MSH-based numbering). Moreover, in general, most of the
linear short α-MSH(4−10)-derived peptides are less potent
than either MT-II or its cyclic heterodetic “clicked” MT-II-
derived peptides I−X.
Neither MT-II nor the 1,4- and 4,1-disubstituted-[1,2,3]-
triazolyl-containing cyclopeptides I−X show very high
selectivity toward a speciﬁc receptor subtype, and there is no
consistent trend for receptor subtype selectivity in the
[1,2,3]triazolyl-contaning analogue series (Table 3, Figure 2).
For example, while MT-II is 3−6-fold more potent toward
mMC1R and mMC4R (cf. EC50s 0.03 and 0.06 nM on
Table 1. Sequences of MT-II, the Classical NDP-MSH, and







Table 2. Functional Potency (EC50) of Linear Peptide
Precursors Nα-Ac[Nle4,Yaa5,D-Phe7,Xaa10]αMSH(4−10)NH2
(I′, II′, III′, IV′, and IX′) and Nα-Ac[Nle4,Xaa5,D-
Phe7,Yaa10]αMSH(4-10)NH2 (V′, VI′, VII′, VIII′, and X′)a
aEC50 of NDP-MSH, BE123, and BE124 are reported as references.
Notations: Pra, L-propargylglycine; Nva, L-norvaline; hAla, L-
homoalanine; Hex, L-α-amino hexanoic acid; Hept, L-α-amino
heptanoic acid; Oct, L-α-amino octanoic acid. bAgonist potencies
(EC50) of the lactam containing peptide (MT-II) in mMC1R,
mMC3R, mMC4R, and mMC5R are 0.03, 018, 0.06, and 0.19 nM,
respectively. cThe detailed sequences are given in Table 1. dn.d. means
not determined.
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mMC1R and mMC4R, respectively, with 0.18 and 0.19 nM on
mMC3R and mMC5R, respectively), the maximal selectivity
observed for the least potent analogues I and V toward the
diﬀerent receptor subtypes is 2−3-fold and 3−6-fold,
respectively (EC50s 1.62, 3.14, and 5.18 nM of analogue I in
mMC4R, mMC3R, and mMC1R, respectively, and 0.58, 1.76,
and 3.70 nM of analogue V in mMC4R, mMC5R, and
mMC3R, repectively). The most potent [1,2,3]triazolyl-
contaning analogues in this series are III, IV, VII, and X.
They all have preference to the mMC4R and mMC5R (EC50s
0.051, 0,041, 0.048, and 0.067 nM, respectively, on the former
receptor subtype, and 0.042, 0.035, 0.045, and 0.07 nM,
respectively, on the latter one) and analogues IV and VII are
active to a lesser extent on mMC1R (EC50s 0.087 and 0.074
nM, respectively).
[1,2,3]Triazolyl-contaning analogues I−VIII share a common
location of the bridgeheads (positions 5 and 10) and an
identical size of the bridges (ﬁve methylenes in total and a 1,4-
disubstituted [1,2,3]triazolyl moiety). As such, they are loosely
reproducing the features of the lactam bridge in MT-II (ﬁve
methylenes in total and one amide bond). However, these
heterodetic cyclopeptides diﬀer in the location of the
[1,2,3]triazolyl moiety within the bridge, so one or two
methylenes are removed from the N-proximal bridgehead
(analogues I and VIII and II and VII, respectively) or one or
two methylenes from the C-proximal bridgehead (analogues IV




2}] (I, II, III, IV, and IX) and Nα-
Ac[Nle4,Xaa5(&1),D-Phe7,Yaa10(&2)]αMSH(4-10)NH2 [{&
1(CH2)m-4,1-[1,2,3]triazolyl-(CH2)n&
2}] (V, VI, VII, VIII, and X)a
aEC50 of MT-II is reported as reference.
Figure 1. Logarithmic graphical representation of functional agonist
activity (EC50 in nM) of linear peptide precursors (I′−X′).
Figure 2. Logarithmic graphical representation of agonist potency
(EC50 in nM) of the [1,2,3]triazolyl-containing cyclopeptides (I−X).
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and V and III and VI, respectively). The location of the
[1,2,3]triazolyl moiety within the bridge in analogues I and VIII
is identical with the location of the isosteric amide within the
lactam bridge in MT-II. Evidently, I and VIII are less potent
than MT-II in mMC1R, mMC3R, and mMC4R (Table 3).
Moreover, I, which incorporates a 4,1-[1,2,3]triazolyl moiety, is
much less potent than VIII, which incorporates a 1,4-
[1,2,3]triazolyl moiety. Interestingly, analogue VII, which
incorporates the 1,4-[1,2,3]triazolyl, is more potent than
analogue II, which incorporates the 4,1-[1,2,3]triazolyl moiety
despite the [1,2,3]triazolyl moiety at the same position in the
bridge. In both pairs I and VIII and II and VII, where the
position of the [1,2,3]triazolyl ring is closer to the N-proximal
bridgehead, the more potent analogues VII and VIII are those
that incorporate the 1,4-[1,2,3]triazolyl moiety. On the
contrary, in both pairs IV and V and III and VI, where the
position of the [1,2,3]triazolyl ring is closer to the C-proximal
bridgehead, the more potent analogues III and IV are those that
incorporate the 4,1-[triazolyl] moiety. Analogues IX and X have
a shorter bridge than analogues I−VIII (four methylenes in
total and a 1,4-disubstituted [1,2,3]triazolyl moiety), and the
[1,2,3]triazolyl moiety is ﬂanked by two methylenes on each
side in either the 4,1- or 1,4-orientation. Moreover, analogues
IX and X diﬀer in the orientation of the [1,2,3]triazolyl moiety,
which is positioned equal distance from the bridgeheads, being
4,1 in the former and 1,4 in the latter. While both IX and X are
more potent at mMC4R and mMC5R than on mMC1R and
mMC3R, the activities of analogue IX and X diﬀer by the latter
being more potent at the two former receptor subtypes, thus
being more selective than analogue IX. The potency proﬁles of
analogues IX and X (EC50s 0.32, 0.63, 0.14, and 0.15 nM and
0.20, 0.29, 0.067, and 0.07 nM at mMC1R, mMC3R, mMC4R,
and mMC5R, respectively) follow very closely that of the
corresponding analogues VIII and III (EC50s 0.53, 0.60, 0.14,
and 0.13 nM and 0.1, 0.21, 0.051, and 0.042 nM at mMC1R,
mMC3R, mMC4R, and mMC5R, respectively).
Taken together, these results suggest that close proximity of
the [1,2,3]triazolyl moiety to the N-proximal bridgehead,
especially in the 4,1-orientation, is disruptive for activity at all
four receptor subtypes (analogues I and VIII, respectively).
Interestingly, close proximity of the [1,2,3]triazolyl moiety to
the C-proximal bridgehead as in analogues V and IV, presenting
the [1,2,3]triazolyl in the respective 1,4- and 4,1-orientations,
results in an opposite eﬀect in which it is very disruptive for the
former and very accommodating for the latter for all four
receptor subtypes. Of note is the higher activity of the linear
precursors I′ and V′ on the mMC1R as compared to the
activity of the corresponding [1,2,3]triazolyl-containing cyclo-
peptides I and V on the same receptor subtype (EC50s 0.46 and
0.24 nM vs 5.18 and 0.85 nM). This may be the result of the
serious perturbation imposed by the 4,1-[1,2,3]triazolyl moiety
when it is adjacent to the N-proximal bridgehead and to a lesser
extent, regardless of the orientation of the [1,2,3]triazolyl ring,
when it is adjacent to the C-proximal bridgehead.
The comparison of the activity proﬁle of the linear peptide
precursors and their corresponding [1,2,3]triazolyl-containing
cyclopeptides indicates the latter, in general, to be slightly more
potent. Clearly, the linear precursors are already very potent
indicating that the conformational rigidiﬁcation in the cyclo-
peptide is not critical for their high potency. Moreover, only in
very few cases the linear precursor peptides are more potent
than their corresponding [1,2,3]triazolyl-containing cyclo-
peptides (cf. I′ and V′ with I and V in mMC1R, respectively).
Conformational Analysis. To gain insight on the
relationship among the speciﬁc features of the [1,2,3]-
triazolyl-containing bridge, the potency and receptor subtype
selectivity, and the conformation, we selected to study in detail
the conformations of three representative heterodetic [1,2,3]-
triazolyl-containing cyclopeptides, I, IV, and V. The selection
includes the least potent analogue I, one of the most potent
analogues IV, and analogue V of intermediate potency. In
addition, while analogues I and IV incorporate the 4,1-
[1,2,3]triazolyl moiety in proximity to the N-proximal- and
C-proximal bridgeheads, respectively, both analogues IV and V
incorporate the [1,2,3]triazolyl moiety at the C-proximal
bridgehead but at opposite orientations, 4,1- and 1,4-,
respectively. We anticipated that the opposing location of the
[1,2,3]triazolyl ring in the bridge will aﬀect the conformation to
the extent that will explain the large diﬀerence in activity
between analogues I and IV. On the other hand, we speculate
that the small diﬀerence in biological activity between
analogues IV and V, which share the same C-proximal
bridgehead location of the [1,2,3]triazolyl ring, may result in
similar conformations in spite of the opposite orientations of
the [1,2,3]triazolyl ring within the bridge.
To allow comparison with the reported “bioactive” NMR
solution structure(s) of the reference homodetic cyclopeptide
MT-II, the NMR spectra of the heterodetic cyclopeptides I, IV,
and V were acquired in DMSO-d6.
30 Moreover, this polar,
basic, and aprotic solvent was shown to support intramolecular
hydrogen bonds and prevent intermolecular aggregations.31,32
To exclude potential aggregation, we recorded the 1D-1H NMR
spectra of the clicked-cyclopeptides at a concentration range
spanning 1−0.1 mM. Importantly, at a concentration of 0.1
mM, there was no indication for aggregation. Nevertheless, at
0.1 mM, cyclopeptide I presented double signal pattern spectra
indicating the presence of two distinct populations of slow
exchanging conformations. Chemical shift assignments of the
proton spectra were achieved via the standard systematic
application of DQF-COSY,33 TOCSY,34 and NOESY35 experi-
ments, using the SPARKY36 software package according to
Wüthrich’s procedure.37
Figure 3 reports sequential and medium range NOEs
collected in NOESY spectra of cyclopeptides I, IV, and V in
DMSO-d6, conﬁrming the preliminary analysis of 1D-
1H NMR
spectrum. Two NOEs bar diagrams are reported for [1,2,3]-
triazolyl-containing cyclopeptide I, corresponding to the
observed double signal pattern in the respective NOESY
spectrum (Figure 3A,B). The conformer IA is characterized by
a more complete sequential and medium range NOE pattern,
while conformer IB shows less abundant and, whenever
observable, weak, sequential, and medium range connectivities.
This observation is consistent with the presence of the two
predominant low energy conformational ensembles IA and IB,
undergoing slow dynamic interchange. We suggest that the
markedly low potency of cyclopeptide I compared to
cyclopeptides IV and V in all melanocortin receptor subtypes
(EC50s 5.18, 3.14, 1.62, and 1.93 nM for mMC1R, mMC3,
mMC4R, and mMC5R, respectively) can be attributed to this
conformational heterogeneity. NOE bar diagrams relative to
cyclopeptides IV and V (parts C and D of Figure 3,
respectively), conﬁrm the presence of numerous and diagnostic
sequential and medium range i,i+2 and i,i+3 NOE data in the
corresponding NOESY spectra, although a more regular and
complete NOE patterns is observed for cyclopeptide V than for
cyclopeptide IV. NMR-derived models of cyclopetides IA, IV,
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and V were calculated using simulated annealing procedures
imposing NOE-based interprotonic distances as constraints.
Figure 4 shows the NMR-derived bundles of 20 low energy
conformations of cyclopeptides IA, IV, and V overlapping with
the best calculated structure of MT-II. The NMR structure
bundles of cyclopeptides IA and V show high structural
agreement with RMSD ∼ 0.50 Å. In agreement with the NOE
bar diagrams reported in Figure 3, the structure bundle of
cyclopeptide IV is characterized by slightly higher RMSD value
(0.80 Å), indicating that cyclopeptide IV is more ﬂexible than
cyclopeptides IA and V.
Quantitative analysis of φ and ψ (Supporting Information,
Table 1S) dihedral angles of low-energy structures of
cyclopeptides IA, IV, and V, using the PROMOTIF program
(PROMOTIF, a program to identify and analyze structural
motifs in proteins)38 highlights the preponderance of a type I β-
turn conformation centered on residues His6-Trp9. In agree-
ment with the preliminary analysis shown in the NOESY
connectivity bar diagram (Figure 3), cyclopeptide IB appears to
be disordered, presenting many irregular secondary structures
including some transient α-helical segments.
The comparison of the 20 lowest-energy NMR structures of
cyclopeptides IA, IV, and V (Figure 4) suggests good overlap of
the backbone atoms and a common orientation of His and D-
Phe side chains. Cyclopeptides IV and V show also a common
orientation of the indole ring of Trp.
As shown in Figure 4a the Trp side chain of cyclopeptide IA
points to an opposite direction as compared to cyclopeptide IV
and V. Moreover, the three cyclopeptides diﬀer in the
orientation of the Arg side chain. In cyclopeptides IV and V,
as documented by the relative NOE eﬀects, Arg side chains
point to [1,2,3]triazolyl ring and D-Phe moiety, respectively
(Figure 4a). Consistent with the absence of NOEs suggesting
proximity to other side chains, Arg side chain in cyclopeptide
IA, displays signiﬁcantly higher ﬂexibility than in analogues IV
and V (Figure 4a,b).
Stabilization of a type II β-turn because of D-Phe and the
close proximity of His, D-Phe, and Trp side chains on one of the
homodetic cyclopeptide surface and Arg side chain on the
opposite surface in MT-II can explain the high potency and
aﬃnity to the melanocortin receptors.39,40 It is known that a
correct spatial orientation of the hydrophobic aromatic residues
and the basic, “arginine-like” moiety, are important for an
eﬀective interaction of MT-II and MT-II analogues at the
diﬀerent MCR receptors.30
In summary, conformational analysis of the three selected
heterodetic [1,2,3]triazolyl-containing MT-II analogues sug-
gests that (i) the conformational polymorphism of cyclopeptide
I contributes to its overall low potency in all receptor subtypes
as compared to the more conformationally deﬁned cyclo-
peptides IV and V, and (ii) the presence, location, and
orientation of the [1,2,3]triazolyl ring in the bridge does aﬀect
the spatial location of the side chains in general and of the Arg
side chain in particular. It appears that biological activity is
derived from indirect contribution to the spatial orientations of
side chains more then by the direct interaction of the bridge
with the target receptor.
■ CONCLUSIONS
In the present paper, we report for the ﬁrst time a systematic
structure−activity conformation relationship study in which a i-
to-i+5 side chain-to-side chain CuI-catalyzed azido-to-alkyne
1,3-dipolar cycloaddition (CuAAC) was performed in an
attempt to reproduce a type I β-turn, which is considered to
be a critical feature in the putative bioactive conformation of
MT-II. We demonstrate that (1) i-to-i+5 side chain-to-side
chain CuAAC yields potent and interesting melanocortin
receptor agonists; (2) side chain-to-side chain conformational
stabilization of type I β-turn by i-to-i+5 side chain-to-side chain
[1,2,3]triazolyl-containing bridges impacts the in vitro potency
and selectivity of these new stapled peptides at the diﬀerent
MCR receptor subtypes. Relative to MT-II, we frequently
observe enhancement of potency at the mMC5R and loss of
potency at mMC1R. (3) Similar to the general enhancement of
potency as a result of homodetic side chain-to-side chain
cyclization (cf. BE124 and BE123 with MT-II, Table 2), we also
observe enhancement of potency upon transforming the linear
precursors I′−X′ to the heterodetic [1,2,3]triazolyl-containing
cyclopeptides. Interestingly, similar observation was reported
by Cho et al. in i-to-i+5 disulﬁde-bridged cyclic MSH
peptides.41 (4) Regardless of the nature of i-to-i+5 side
chain-to-side chain cyclizations, their contribution to the
stability of the critical type I β-turn contributes to the
enhancement of their agonisit potency at all MCRs. Our
observations concur with those that propose side chains
orientation of residues within the cyclic segment and those
that are ﬂanking it to play a predominant role in determining
receptor subtype selectivity. As such, the i-to-i+5 side chain-to-
side chain CuAAC oﬀers obvious advantages over the more
traditional side chain-to-side chain cyclizations. These hetero-
detic [1,2,3]triazolyl-containing MT-II mimetics can be
Figure 3. Sequential and medium-range NOEs for [1,2,3]triazolyl-
containing cyclopeptides IA (A), IB (B), IV (C), and V (D). (A) and
(B) are derived from to the NOE connectivities of the most (IA) and
the lesser (IB) abundant conformers of I. Data were obtained from a
600 MHz NOESY experiments with a mixing time of 200 ms and
collected in DMSO-d6 at 300 K.
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constructed by taking advantage of the chemical orthogonality
of the azido and alkynyl functions, which reduces synthetic
complexity. Moreover, our approach oﬀers access to a vast
structural diversity presented by the size of the bridge, the
location, and the orientation of the [1,2,3]triazolyl moiety
within the ring. In the future, we will seek to reduce the size of
the [1,2,3]triazolyl-containing bridge to achieve greater
structural rigidiﬁcation and diversify the nature of the residues
ﬂanking the cyclic segment in order to achieve greater receptor
subtype selectivity.
■ EXPERIMENTAL SECTION
Materials and Methods. The ω-alkynyl-alcohols were purchased
from Alfa Aesar; Fmoc-L-Trp-(Boc)-OH, Fmoc-D-Phe-OH, and Fmoc-
L-Pra-OH amino acids, Fmoc-Rink amide resin, and HOBt were
purchased from Iris Biotech GmbH (Marktredwitz, Germany); Fmoc-
L-Arg(Pbf)-OH and Fmoc-L-His(Trt)-OH amino acids were pur-
chased from CBL (Patras, Greece); Fmoc-L-Nle was purchased from
NeoMPS (Strasbourg, France); TBTU from Advanced Biotech Italy
(Milan, Italy). Peptide-synthesis grade N,N-dimethylformamide
(DMF) was purchased from Scharlau (Barcelona, Spain); acetonitrile
from Carlo Erba (Milan, Italy); dichloromethane (DCM), triﬂuoro-
acetic acid (TFA), piperidine, acetic anhydride (Ac2O), and N-methyl
morpholine (NMM) were purchased from Sigma-Aldrich (Milan,
Italy). The scavengers for cleavage of peptides from resin, 1,2-
ethanedithiol (EDT), thioanisole, and phenol (PhOH), were
purchased from Acros Organics (Geel, Belgium), Jansenn Chimica
(Beerse, Belgium), and Carlo Erba (Milan, Italy).
The purity of the ﬁnal linear precursors (I′−X′) and the
[1,2,3]triazolyl-containing MT-II analogues (I−X) was established
by analytical RP-HPLC and exceeded 95%, their structural integrity
was established by ESI-MS.
Synthesis of Nα-Fmoc-Xaa(ω-N3)-OH and N
α-Fmoc-Yaa(ω-
yl)-OH. Nα-Fmoc-ω-azido-α-amino- and Nα-Fmoc-ω-ynoic-α-amino
acids (1−4 and 5−7, respectively), with (CH2)n/m n/m = 1−4 in the
side chain, were synthesized as described before.21,22 In particular, Nα-
Fmoc-ω-azido-α-amino acids were obtained by diazo-transfer from
correspondent Nα-Fmoc-ω-amino-α-amino acids; Nα-Fmoc-ω-ynoic-
α-amino acids were obtained by alkylation of a Ni(II) complex of the
Schiﬀ base derived from glycine and the chiral inducer (S)-2-(N-
benzylprolyl)aminobenzophenone with alk-ω-ynyl bromides.
Synthesis of Nα-Ac[Nle4,Yaa5,D-Phe7,Xaa10]αMSH(4−10)NH2
(I′, II′, III′, IV′, IX′) and Nα-Ac-[Nle4,Xaa5,D-Phe7,Yaa10]αMSH-
(4−10)NH2 (VI′, V′, VII′, VIII′, X′). Peptides I′−X′ were synthesized
on a manual batch synthesizer (PLS 4 × 4, Advanced ChemTech)
employing Fmoc/tBu chemistry. The syntheses were performed on
Rink-amide NovaSyn TGR resin (0.14 mmol/g, 300 mg). The Fmoc-
Rink-amide resin was swelled with DMF (1 mL/100 mg of resin) for
20 min before use. Stepwise peptide assembly was performed by
repeating for each added amino acid the following deprotection-
coupling cycle. (1) Swelling: DMF (1 mL/100 mg of resin) for 5 min.
(2) Fmoc-deprotection: resin was washed twice with 20% (v/v)
piperidine in DMF (1 mL/100 mg of resin, one wash for 5 min,
followed by another wash for 20 min). (3) Resin washing: DMF (3−5
min). (4) Coupling: scale employed TBTU/HOBt/NMM (2.5:2.5:3.5
equiv) as the coupling system and 2.5 equiv of the Fmoc protected
amino acids, except for the unnatural amino acids Nα-Fmoc-Xaa(ω-
N3)-OH and N
α-Fmoc-Yaa(ω-yl)-OH, for which 1.5 equiv were used.
The coupling was carried out in DMF (1 mL/100 mg of resin) for 50
min. (5) Resin washings: DMF (3−5 min) and DCM (1−5 min).
Each coupling was monitored by Kaiser test42 and was negative,
therefore recouplings were not needed. Acetylation of the amino
terminus was carried out in the presence of Ac2O/NMM in DCM (20
equiv, 1.6 mL of DCM). The reaction was monitored by Kaiser test.
Deprotection, Cleavage, and Puriﬁcation of Peptides:
General Procedure. Peptide cleavage from the resin and
simultaneous deprotection of the amino acid side chains were carried
out with a mixture of TFA/anisole/1,2-ethanedithiol/phenol/H2O
(94:1:1:1:1 v/v/v/v/v, 1 mL/100 mg of resin-bound peptide). The
cleavage was carried out for 3 h with vigorous shaking at room
temperature. Resin was ﬁltered and washed with TFA. The ﬁltrate was
concentrated under N2 stream, addition of cold diethyl ether resulted
in a precipitate that was separated by centrifugation, dissolved in H2O,
Figure 4. (a) Overlay of NMR-derived calculated structure bundles of IA, the most abundant conformational ensemble (left), IV (middle), and V
(right), all wireframe structures, compared with the best calculated structure of MT-II (ribbon structure). (b) Side chain orientation of cyclopeptides
IA, IV, and V. Residue side chains are colored as follow: L-His, light gray; D-Phe, pink; L-Arg, red; L-Trp, blue.
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and lyophilized on an Edwards apparatus, model Modulyo.
Lyophilized crude peptides were prepuriﬁed by solid-phase extraction
with a RP-18 LiChroprep silica column from Merck (Darmstadt,
Germany) using H2O/ACN as eluents. The ﬁnal puriﬁcation of the
peptides was performed by semipreparative RP-HPLC on a
Phenomenex Jupiter C-18 (250 mm × 4.6 mm) column at 28 °C
using a Waters instrument (separation module 2695, detector diode
array 2996) working at 4 mL/min. The solvent systems used were: A
(0.1% TFA in H2O) and B (0.1% TFA in CH3CN). Final purity of all
peptides was ≥95%. Peptides were characterized by RP-HPLC ESI-
MS. HPLC system was an Alliance Chromatography (Waters) with a
Phenomenex Kinetex C-18 column 2.6 μm (100 mm × 3.0 mm)
working at 0.6 mL/min, with UV detection at 215 nm, coupled to a
single quadrupole ESI-MS (Micromass ZQ). The solvent systems used




2}] (I, II, III, IV, IX)
and Nα-Ac[Nle4,Xaa5(&1),D-Phe7,Yaa10(&2)]αMSH(4−10)NH2
[{&1(CH2)m-1,4-[1,2,3]triazolyl-(CH2)n&
2}] (V, VI, VII, VIII, X).
Puriﬁed linear peptide precursors I′−X′ (>95% purity) were subjected
to intramolecular CuI-catalyzed side-chain-to-side-chain azide−alkyne
1,3-dipolar Huisgen cycloaddition (CuAAC). To a solution of the
puriﬁed linear peptide (4.77 μmol) in H2O/tBuOH (5 mL, 2:1 v/v)
were added CuSO4·5H2O (40 μmol) and ascorbic acid (40.3 μmol).
The mixture was stirred overnight at room temperature, concentrated,
and lyophilized. Complete and clean conversion of all linear precursors
into the desired [1,2,3]triazolyl-containing cyclopeptides I−X
(Schemes 1 and 2) was observed. The cyclization was monitored by
RP-HPLC ESI-MS. The crude [1,2,3]triazolyl-containing cyclo-
peptides were puriﬁed (>97% purity) by solid-phase extraction
(SPE) on RP (C18) column, with CH3CN in H2O as eluents. The
copper salts were removed by elution with H2O, whereas the desired
cyclopeptides were eluted with CH3CN/H2O mixture. Peptides were
puriﬁed and characterized by semipreparative RP-HPLC and RP-
HPLC ESI-MS, respectively.
Solid Phase Synthesis of MT-II: Nα-Ac[Nle4-c(Asp5-D-Phe7-
Lys10)]αMSH(4−10)NH2. The fully protected resin-bound peptide
was synthesized using a Rink-amide NovaSyn TGR resin (0.63 mmol/
g, 300 mg) on a manual batch synthesizer (PLS 4 × 4, Advanced
ChemTech) applying the Fmoc/tBu SPPS procedure, as previously
reported. The coupling of Nα-Fmoc-amino acids was performed using
TBTU/HOBt/NMM (2.5 equiv:2.5 equiv:3.5 equiv) and 2.5 equiv of
each Fmoc protected amino acids. The coupling was carried out in
DMF (1 mL/100 mg of resin) for 40 min. The formation of the lactam
bridges between side chains of Lys10 and Asp5 was performed on the
resin-bound peptide, following an orthogonal protocol of depro-
tection. In particular, Lys10 and Asp5 were protected on side chain
respectively with 1-[(4,4-dimethyl-2,6-dioxocyclohex-1-ylidine)ethyl]
group (Dde) and with β-4-{N-[1-(4,4-dimethyl-2,6-dioxocyclohexyli-
dene)-3-methylbutyl]-amino} benzyl ester (ODmab), stable under the
conditions of peptide elongation. After acetylation of the N-terminal,
Dde and ODmab were removed by two consecutive steps, using
hydrazine 20% in DMF (1 mL), ﬁrst for 5 min, followed by an
additional step with freshly prepared deprotection mixture for 15 min.
After deprotection of Lys10 and Asp5, the formation of intramolecular
lactam bridge was performed using TBTU/HOBt/NMM (2.5:2.5:3.5
equiv) as coupling system in DMF for 40 min. The cyclization reaction
was monitored by Kaiser test and by RP-HPLC ESI-MS analysis of
MW-assisted mini-cleavage resin-bound fragment. Mini-cleavage was
carried out with TFA/TIS/water solution (95:2.5:2.5 v/v/v), using a
DiscoverTMS-class single-mode MW reactor equipped with an
Explorer-48 autosampler (CEM). The reaction was performed at 45
°C, using 15 W for 15 min. The reaction mixture was then ﬁltered, and
the crude peptide was precipitated from the cleavage mixture by
addition of ice-cold diethyl ether followed by cooling for 5 min at −20
°C. The product was collected by centrifugation and directly subjected
to RP-HPLC ESI-MS analysis.
Biological Activity. cAMP based functional bioassay: HEK-293
cells stably expressing the mouse melanocortin receptors were
transiently transfected with 4 μg of CRE/β-galactosidase reporter
gene as previously described.28,29,43,44 Brieﬂy, 5000−15000 post
transfection cells were plated into collagen treated 96-well plates
(Nunc) and incubated overnight.
Then 48 h post-transfection, the cells were treated with 100 μL of
peptide (10−6−10−12 M) or forskolin (10−4 M) as a control in assay
medium (DMEM containing 0.1 mg/mL BSA and 0.1 mM
isobutylmethylxanthine) for 6 h. The assay media was aspirated, and
50 μL of lysis buﬀer (250 mM Tris-HCl pH = 8.0 and 0.1% Triton X-
100) was added. The plates were stored at −80 °C overnight. The
plates containing the cell lysates were thawed the following day.
Aliquots of 10 μL were taken from each well and transferred to
another 96-well plate for relative protein determination. To the cell
lysate plates, 40 μL of phosphate-buﬀered saline with 0.5% BSA was
added to each well. Subsequently, 150 μL of substrate buﬀer (60 mM
sodium phosphate, 1 mM MgCl2, 10 mM KCl, 5 mM β-
mercaptoethanol, 2 mg/mL ONPG) was added to each well, and
the plates were incubated at 37 °C. The sample absorbance, OD405,
was measured using a 96-well plate reader (Molecular Devices). The
relative protein concentration was determined by adding 200 μL of 1:5
dilution Bio Rad G250 protein dye:water to the 10 μL cell lysate
sample taken previously, and the OD595 was measured on a 96-well
plate reader (Molecular Devices). Data points were normalized to the
relative protein content. EC50 values represent the mean of three or
more independent experiments. EC50 estimates, and their associated
standard errors of the mean, were determined by ﬁtting the data to a
nonlinear least-squares analysis using the PRISM program (v4.0,
GraphPad Inc.).
NMR Conformational Analysis. Samples for NMR were
prepared by dissolving 1.2 mg of the lactam- and heterodetic
[1,2,3]triazolyl-containing cycloheptapeptides in 0.5 mL of aqueous
phosphate buﬀer (pH 6.6, 100 mM). Samples were lyophilized and
dissolved in a mixture of DMSO/water (0.5 mL, 80:20, v/v). NMR
spectra were recorded on a Bruker DRX-600 spectrometer. To exclude
potential aggregation, one-dimensional (1D) proton spectra of the
cyclopeptides at a concentration range spanning 0.1−1 mM were
recorded. At a peptide concentration of 0.1 mM, the peptides did not
display any noticeable eﬀects of aggregation. 1D NMR spectra were
recorded in the Fourier mode with quadrature detection. The water
signal was suppressed by a low-power selective irradiation in the
homogated mode. DQF-COSY, TOCSY, and NOESY experiments
were run in the phase-sensitive mode using quadrature detection in ω1
by time-proportional phase incrementation of the initial pulse. Data
block sizes comprised of 2048 addresses in t2 and 512 equidistant t1
values. Before Fourier transformation, the time domain data matrices
were multiplied by shifted sin2 functions in both dimensions. A mixing
time of 70 ms was used for the TOCSY experiments. NOESY
experiments were run at 300 K with mixing times in the range of 100−
250 ms. The qualitative and quantitative analyses of DQF-COSY,
TOCSY, and NOESY spectra were obtained using the SPARKY
interactive program package. Complete proton resonance assignments
were achieved following Wüthrich’s procedure. Sequential and
medium range Nuclear Overhauser Eﬀects (NOEs)-derived distances
were used to generate 3D-models of the heterodetic [1,2,3]triazolyl-
containing cyclo-heptapeptides. The ﬁnal PDB ﬁles were analyzed and
validated using PROMOTIF software.
NMR Structure Calculation. On the basis of sequential and
medium range NOE derived distances, 3D models of lactam- and
[1,2,3]triazolyl-containing peptides were generated with a simulated
annealing procedure using the DYANA software package. All
structures were energy minimized with the SANDER module of the
AMBER 5 program, using for 1000 steps the steepest descent method
and for 4000 steps the conjugate gradient method. A nonbonded
cutoﬀ of 12 Å and a distance-dependent dielectric term (e = 4 × r)
were used. The minimization protocol included three steps in which
NOE derived distances were used as constraints with a force constant,
respectively, of 1000, 100, and 10 kcal/molÅ. The ﬁnal PDB ﬁles were
analyzed and validated using PROCHECK software.
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